Doxazosin Mesylate

甲磺酸多沙唑嗪

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameDoxazosin Mesylate
Drug Alias Name多赛唑嗪甲磺酸盐DiblocinSupressin甲磺酸多赛唑嗪多沙唑嗪甲磺酸盐 +[30] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptor alpha-1 antagonists
TargetsAdrenergic receptors alpha-1
Therapy Area/IndicationsStress Disorders, Post-TraumaticAnxietySmoking Cessation +[11] 
Global Approved IndicationsHypertensionProstatic Hyperplasia
Approved Indications in ChinaHypertensionProstatic Hyperplasia
Original Approved Country/TerritoryNew Zealand
Original Approved Date1986/12/01
Country/TerritoryUnited StatesNew ZealandMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesNorthern California Institute For Research And EducationPfizer IncBrown University +[5] 
Inactive CompaniesViatrisUniversity Of MinnesotaYale University +[7] 
Active IndicationsStress Disorders, Post-TraumaticAlcoholismHypertension +[4] 
Inactive IndicationsAnxietySmoking CessationCocaine-Related Disorders +[7] 

Other Information

ATC CodeC02CA04
Related LinksWikipediaDrugBankKEGG